GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (OTCPK:SNYNF) » Definitions » Investments And Advances

SNYNF (Sanofi) Investments And Advances : $2,842 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sanofi Investments And Advances?

Sanofi's Investments And Advances for the quarter that ended in Jun. 2024 was $2,842 Mil.

Sanofi's quarterly Investments And Advances increased from Jun. 2023 ($2,763 Mil) to Dec. 2023 ($2,907 Mil) but then declined from Dec. 2023 ($2,907 Mil) to Jun. 2024 ($2,842 Mil).

Sanofi's annual Investments And Advances increased from Dec. 2021 ($2,737 Mil) to Dec. 2022 ($2,929 Mil) but then declined from Dec. 2022 ($2,929 Mil) to Dec. 2023 ($2,907 Mil).

Sanofi Investments And Advances Historical Data

The historical data trend for Sanofi's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Investments And Advances Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,851.11 2,946.47 2,736.72 2,929.03 2,907.31

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,794.93 2,929.03 2,762.73 2,907.31 2,841.77

Sanofi Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Sanofi Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (OTCPK:SNYNF) » Definitions » Investments And Advances
Comparable Companies
XPAR:VIRP LLY OCSE:NOVO B JNJ ABBV MRK XSWX:ROG XSWX:NOVN LSE:AZN AMGN PFE BMY GILD LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578 BIIB XTER:BAYN
Traded in Other Exchanges
SNY:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria
Address
46, avenue de la Great Army, Paris, FRA, 75017
Website
https://www.sanofi.com
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.